• Acting commissioner refers agency to inspector general
• Biogen Inc’s drug Aduhelm controversially approved last month
The US drug regulator has called for an independent federal investigation into the interactions between its representatives and Biogen Inc that led to the approval of the company’s Alzheimer’s disease drug last month.
The drugmaker’s shares fell 3% after the agency’s acting commissioner, Janet Woodcock, asked the office of the inspector general at the Department of Health and Human Services to investigate if the talks were inconsistent with the regulator’s policies.
Related: We’ve got the first Alzheimer’s drug in decades. But is it a breakthrough?
